tacrolimus
Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.
Cross Reference
Introduction
To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with tacrolimus?
tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
| Disease | Cross reference | Weighted score | Related literature |
|---|
Loading... please refresh the page if content is not showing up.
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with tacrolimus
PubChem Associated disorders and diseases
What pathways are associated with tacrolimus
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with tacrolimus?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
| Location | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What functions are associated with tacrolimus?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with tacrolimus?
Related references are published most in these journals:
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What genes are associated with tacrolimus?
Related references are published most in these journals:
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with tacrolimus?
There are no associated biomedical information in the current reference collection.
NCBI Entrez Crosslinks
All references with tacrolimus
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| de Fijter JW et al. | Early Conversion From Calcineurin Inhibitor- to Everolimus-Based Therapy Following Kidney Transplantation: Results of the Randomized ELEVATE Trial. | 2017 | Am. J. Transplant. | pmid:28027625 |
| Dugast E et al. | Failure of Calcineurin Inhibitor (Tacrolimus) Weaning Randomized Trial in Long-Term Stable Kidney Transplant Recipients. | 2016 | Am. J. Transplant. | pmid:27367750 |
| de Fontbrune FS et al. | Veno-occlusive disease of the liver after lung transplantation. | 2007 | Am. J. Transplant. | pmid:17697264 |
| Krenzien F et al. | Age-Dependent Metabolic and Immunosuppressive Effects of Tacrolimus. | 2017 | Am. J. Transplant. | pmid:27754593 |
| TruneÄka P et al. | Once-daily prolonged-release tacrolimus (ADVAGRAF) versus twice-daily tacrolimus (PROGRAF) in liver transplantation. | 2010 | Am. J. Transplant. | pmid:20840481 |
| Ekberg H et al. | Calcineurin inhibitor minimization in the Symphony study: observational results 3 years after transplantation. | 2009 | Am. J. Transplant. | pmid:19563339 |
| Schubert M et al. | Pharmacokinetics of sirolimus and tacrolimus in pediatric transplant patients. | 2004 | Am. J. Transplant. | pmid:15084173 |
| ter Meulen CG et al. | Steroid-withdrawal at 3 days after renal transplantation with anti-IL-2 receptor alpha therapy: a prospective, randomized, multicenter study. | 2004 | Am. J. Transplant. | pmid:15084178 |
| Borrows R et al. | Steroid sparing with tacrolimus and mycophenolate mofetil in renal transplantation. | 2004 | Am. J. Transplant. | pmid:15476485 |
| Hernández-Fisac I et al. | Tacrolimus-induced diabetes in rats courses with suppressed insulin gene expression in pancreatic islets. | 2007 | Am. J. Transplant. | pmid:17725683 |
| Budde K et al. | Sotrastaurin, a novel small molecule inhibiting protein kinase C: first clinical results in renal-transplant recipients. | 2010 | Am. J. Transplant. | pmid:20121745 |
| Hamdy AF et al. | Comparison of sirolimus with low-dose tacrolimus versus sirolimus-based calcineurin inhibitor-free regimen in live donor renal transplantation. | 2005 | Am. J. Transplant. | pmid:16162204 |
| Kaufman DB et al. | Alemtuzumab induction and prednisone-free maintenance immunotherapy in kidney transplantation: comparison with basiliximab induction--long-term results. | 2005 | Am. J. Transplant. | pmid:16162205 |
| Mujtaba MA et al. | Conversion from tacrolimus to belatacept to prevent the progression of chronic kidney disease in pancreas transplantation: case report of two patients. | 2014 | Am. J. Transplant. | pmid:25179306 |
| Schwarz A et al. | Polyoma virus nephropathy in native kidneys after lung transplantation. | 2005 | Am. J. Transplant. | pmid:16162212 |
| Böger CA et al. | Reverse diastolic intrarenal flow due to calcineurin inhibitor (CNI) toxicity. | 2006 | Am. J. Transplant. | pmid:16889550 |
| Tan HP et al. | Living donor renal transplantation using alemtuzumab induction and tacrolimus monotherapy. | 2006 | Am. J. Transplant. | pmid:16889606 |
| Lucey MR et al. | A comparison of tacrolimus and cyclosporine in liver transplantation: effects on renal function and cardiovascular risk status. | 2005 | Am. J. Transplant. | pmid:15816894 |
| Pillebout E et al. | Renal histopathological lesions after orthotopic liver transplantation (OLT). | 2005 | Am. J. Transplant. | pmid:15816895 |
| Schold JD | The burden of proof in the design of early phase clinical trials. | 2013 | Am. J. Transplant. | pmid:23802723 |
| Chisholm-Burns MA et al. | Improving outcomes of renal transplant recipients with behavioral adherence contracts: a randomized controlled trial. | 2013 | Am. J. Transplant. | pmid:23819827 |
| Van Laecke S et al. | Posttransplantation hypomagnesemia and its relation with immunosuppression as predictors of new-onset diabetes after transplantation. | 2009 | Am. J. Transplant. | pmid:19624560 |
| Pescovitz MD et al. | A randomized, double-blind, pharmacokinetic study of oral maribavir with tacrolimus in stable renal transplant recipients. | 2009 | Am. J. Transplant. | pmid:19663892 |
| Woodle ES et al. | A multicenter pilot study of early (4-day) steroid cessation in renal transplant recipients under simulect, tacrolimus and sirolimus. | 2005 | Am. J. Transplant. | pmid:15636625 |
| Mian AN et al. | Mycoplasma hominis septic arthritis in a pediatric renal transplant recipient: case report and review of the literature. | 2005 | Am. J. Transplant. | pmid:15636628 |
| Gregoor PS and Weimar W | Tacrolimus and pure red-cell aplasia. | 2005 | Am. J. Transplant. | pmid:15636632 |
| Gao R et al. | Effects of immunosuppressive drugs on in vitro neogenesis of human islets: mycophenolate mofetil inhibits the proliferation of ductal cells. | 2007 | Am. J. Transplant. | pmid:17391142 |
| Neuberger JM et al. | Delayed introduction of reduced-dose tacrolimus, and renal function in liver transplantation: the 'ReSpECT' study. | 2009 | Am. J. Transplant. | pmid:19120077 |
| Momper JD et al. | The impact of conversion from prograf to generic tacrolimus in liver and kidney transplant recipients with stable graft function. | 2011 | Am. J. Transplant. | pmid:21714845 |
| Lemahieu WP et al. | CYP3A4 and P-glycoprotein activity in healthy controls and transplant patients on cyclosporin vs. tacrolimus vs. sirolimus. | 2004 | Am. J. Transplant. | pmid:15307840 |
| Fan DM et al. | Successful ABO-incompatible living-related intestinal transplantation: a 2-year follow-up. | 2015 | Am. J. Transplant. | pmid:25808777 |
| Russ GR et al. | Efficacy of sotrastaurin plus tacrolimus after de novo kidney transplantation: randomized, phase II trial results. | 2013 | Am. J. Transplant. | pmid:23668931 |
| RodrÃguez-Perálvarez M et al. | Tacrolimus trough levels, rejection and renal impairment in liver transplantation: a systematic review and meta-analysis. | 2012 | Am. J. Transplant. | pmid:22703529 |
| Luan FL et al. | Comparative risk of impaired glucose metabolism associated with cyclosporine versus tacrolimus in the late posttransplant period. | 2008 | Am. J. Transplant. | pmid:18786231 |
| Woywodt A et al. | Different preparations of tacrolimus and medication errors. | 2008 | Am. J. Transplant. | pmid:18786238 |
| Senior PA et al. | Changes in renal function after clinical islet transplantation: four-year observational study. | 2007 | Am. J. Transplant. | pmid:17227560 |
| Levi Z et al. | Switching from tacrolimus to sirolimus halts the appearance of new sebaceous neoplasms in Muir-Torre syndrome. | 2007 | Am. J. Transplant. | pmid:17229076 |
| Mulay AV et al. | Impact of immunosuppressive medication on the risk of renal allograft failure due to recurrent glomerulonephritis. | 2009 | Am. J. Transplant. | pmid:19353768 |
| Ogawa T et al. | Rho-associated kinase inhibitor reduces tumor recurrence after liver transplantation in a rat hepatoma model. | 2007 | Am. J. Transplant. | pmid:17229077 |
| Miriuka SG et al. | mTOR inhibition induces endothelial progenitor cell death. | 2006 | Am. J. Transplant. | pmid:16796720 |
| Mazariegos GV et al. | Dendritic cell subset ratio in tolerant, weaning and non-tolerant liver recipients is not affected by extent of immunosuppression. | 2005 | Am. J. Transplant. | pmid:15643991 |
| Bahra M et al. | MMF and calcineurin taper in recurrent hepatitis C after liver transplantation: impact on histological course. | 2005 | Am. J. Transplant. | pmid:15644002 |
| Rostaing L et al. | Alefacept combined with tacrolimus, mycophenolate mofetil and steroids in de novo kidney transplantation: a randomized controlled trial. | 2013 | Am. J. Transplant. | pmid:23730730 |
| Levy G et al. | REFINE: a randomized trial comparing cyclosporine A and tacrolimus on fibrosis after liver transplantation for hepatitis C. | 2014 | Am. J. Transplant. | pmid:24456049 |
| Posselt AM et al. | Islet transplantation in type 1 diabetics using an immunosuppressive protocol based on the anti-LFA-1 antibody efalizumab. | 2010 | Am. J. Transplant. | pmid:20659093 |
| Ciancio G et al. | Advantage of rapamycin over mycophenolate mofetil when used with tacrolimus for simultaneous pancreas kidney transplants: randomized, single-center trial at 10 years. | 2012 | Am. J. Transplant. | pmid:22946986 |
| Jacobson PA et al. | Lower calcineurin inhibitor doses in older compared to younger kidney transplant recipients yield similar troughs. | 2012 | Am. J. Transplant. | pmid:22947444 |
| Echeverri GJ et al. | Endoscopic gastric submucosal transplantation of islets (ENDO-STI): technique and initial results in diabetic pigs. | 2009 | Am. J. Transplant. | pmid:19775318 |
| Gaston RS et al. | Fixed- or controlled-dose mycophenolate mofetil with standard- or reduced-dose calcineurin inhibitors: the Opticept trial. | 2009 | Am. J. Transplant. | pmid:19459794 |
| Miller LW | Cardiovascular toxicities of immunosuppressive agents. | 2002 | Am. J. Transplant. | pmid:12392286 |